Home › Trial NCT00258765
Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.
- Trial IDNCT00258765
- StatusTerminated
- PhasePhase 2
- Study typeInterventional
- SponsorNovartis Pharmaceuticals
- Enrollment1
- Start date2006-05
- ConditionsProstate Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.